<DOC>
	<DOCNO>NCT00328809</DOCNO>
	<brief_summary>Cardiovascular disease lead cause death disproportionately prevalent patient kidney disease . Spironolactone show improve survival general population heart failure 30 % . We wish study safety tolerability aldosterone blockade spironolactone cardiac function high risk population patient hemodialysis . We study closely monitor subject period 12 month , receive spironolactone period 6 month .</brief_summary>
	<brief_title>Spironolactone Safety Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>They must least 18 year age . They must understand study purpose give write informed consent . They must stable chronic hemodialysis least three month enrollment study . Hemodialysis subject include leave ventricular ejection fraction measure within past six month value 45 percent . A repeat , standardize echocardiogram use confirm leave ventricular ejection fraction . Subjects primary operable valvular heart disease . Subjects congenital heart disease . Subjects unstable angina . Subjects primary hepatic failure . Subjects active cancer lifethreatening disease ( heart failure endstage renal disease ) . Subjects undergone heart transplantation await heart transplantation also ineligible . Subjects renal transplant list accept study time successful renal transplantation termination dialysis . Subjects habitually difficult control hyperkalemia ( serum potassium &gt; 6.0 meq/L ) previous month dialysis exclude . The inability complete 6minute walk test reason exclude subject study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>